Kewang Pharmaceuticals abandon the production base. Isn't it fragrant?

Kewang Pharmaceuticals abandon the production base. Isn't it fragrant?

Source: Yaozhi.com/Cobe

Unexpectedly, Kewang Pharmaceutical also staged it, "How deeply loved, how decisive it is now lost."

In December 2019, Kewang Pharmaceutical's Suzhou process development and production base laid the foundation in Suzhou Industrial Park, and completed a round B financing of US $ 100 million.

On March 19, 2021, Kewang Pharmaceutical Suzhou process development and Chinese trial production bases were officially completed!

On September 19, 2022, Kewang Pharmaceutical Suzhou's process development and Chinese trial production facilities were absorbed by Yaoming creatures, and reached a "integrated R & D and production" service agreement with Yaoming creatures.

In just a year and a half, the Suzhou craft development and production base, which was most favored at that time, was worked hard, but now it has given Yaoming creatures without regret. CDMO is more attractive?

Create yourself? Or is it better?

(What stage to build, what stage of foundry)

In fact, the BIOTECH enterprise self -built factories and CDMO commissioned who commissioned to produce better disputes. It is a long -term discussion in the Chinese pharmaceutical industry. During this period, no one can accept anyone.

In just a few years, the choice of major pharmaceutical companies in self -built and commissioned production was not only caused by a specific industry environmental trend at that time, but also to the development of the industry.

On May 16, 2019, Tiandong Biological Corporation signed a cooperation agreement with Hangzhou Qiantang New District. The company plans to invest about 5.6 billion yuan to establish an antibody research and development and industrialization base. From R & D, production to commercialization of the entire industrial chain, the determination to transform the entire industrial chain to Biopharma.

Prior to the heavenly biology, Baiji Shenzhou shifted the PD-1 antibody from commissioned Bollinger Yinghan to the commercial development to build a production base of 12 × 2000L in Guangzhou in Guangzhou. in this way.

At that time, the domestic Biotech companies seemed to have an inexplicable plot for the construction of the factory.

So if you are a corporate leader and hold 500 million US dollars, how will you lay out the next strategy? Is it self -built factory?

In this regard, some people have clearly stated that there are four reasons for supporting the enterprise's self -built factories:

One will not be subject to a strong CDMO. Rather than controlling the production session, the price increase of the link is helpless, and it is more conducive to the management of the production link to grasp the production link.

The large -scale production needs of the pharmaceutical market are also forcing enterprises to build factories. The supply of drug production capacity is closely related to whether pharmaceutical companies can participate in commercial competition such as medical insurance. Mass production products with stable quality, reasonable costs, and time -controlled mass production have become key considerations to consider direction. Essence

Under the stimulation of long -term costs and external policies, companies pursue lower production costs, labor costs, and greater control. To a certain extent, the profit of production links is also mastered in one hand, which is more convenient and efficient to control. The cost of the cost of reducing supporting policies and land dividends of various governments is the purpose of reducing the cost of independent factories in pharmaceutical companies.

The fiery biological preparations of the four are higher than small molecular preparations in stable quality than small molecular preparations. Corporation can help enterprises to precipitate core technology in production links.

Of course, some people say that it is not optimistic about the self -built factories of the BIOTECH enterprise. This is simpler, that is, there is no "cost -effective". After all, in the process, whether it is production, management, or quality links, its capital consumption and talent demand are very large, and time and risks are particularly high.

These are very dangerous behaviors for most basic conditions for most basic conditions. It can be said that rashing factories will often become the first step to push the enterprise to the cliff.

Self -built and foundry does not conflict

Of course, in essence, the industry generally believes that when BIOTECH was established in the early days, when listed products were only 1-2, they could consider commissioning production. Essence At the same time, during the period, the attitude and financing of the research management line should be treated according to the capital market. In the case of limited funds, the proportion of production lines and research projects is distributed.

However, the seemingly entrusted production and self -built factories are contradictory two parties, but they are not conflicting. According to relevant persons, the focus of the two division points depends on the needs and orientation of innovative pharmaceutical companies. Based on the choice of enterprises to provide them with services or solutions from clinical to commercialization. Even if the enterprise intends to build a factory in the later period, actively cooperate with the corresponding technical transfer and magnification, and CDMO, which is highly flexible around customer needs, is a trend to adapt to the development of innovative drug companies in the new period.

In fact, in the pharmaceutical industry, the development of Daquan is not either, and it is good for everyone to bear it.

During the Capital Cold Winter, Biotech focused on the strength of the initial period, and pushed the project faster and economically to the market with the help of CDMO. It may be more important to make fame.

For BIOTECH companies, doing the right thing at a suitable stage is the basic law. For CDMO companies, it is the same path to help companies do appropriate things at a suitable stage. The two are actually not conflicting.

After the production phase, should BIOTECH commercialization be flattened?

In November 2021, the cornerstone pharmaceutical and Hengrui reached a cooperation to give the CTLA-4 monoclonal CS1002 in Greater China. It may be as high as 1.185 billion yuan. Prior to this, the cornerstone pharmaceuticals actually had another good authorized authority. The continuous License-out seemed to announce the changes in the operating ideas of the enterprise.

Looking back on the bumps of the cornerstone pharmaceutical industry in the past few years, whether it is the production capacity or the sales team and the R & D platform at the beginning, there is no the same. Later In the same way, the self -built factory building, self -built research and development platform, and self -built sales team. After that, after continuous losses and long -term breaks, the cornerstone pharmaceuticals are now a new look: focusing on research and development, all lying on production and commercialization.

In this regard, perhaps Kewang Pharmaceuticals also have the same consciousness as the cornerstone pharmaceutical industry. Now that the CDMO is handed over to Yaoming creatures, maybe in the future, after the product is listed, it will be commercialized to domestic and foreign medicine leaders.

After all, for innovative drug companies, the products alone are not over, and the ability to commercialization is also an important consideration. Today, for some innovative pharmaceutical companies that have entered the harvest period, the transition from "scientific research orientation" to "market -oriented" transition, production and commercialization are two topics that are inevitable.

After the cornerstone pharmaceutical industry, there are hoping medicines, and there will be countless Biotech after Kewang Medicine, or it will embark on the same path.

Summarize

As far as the incident is concerned, the abandonment of self -built production bases may be a good chess step in cooperation with Yaoming biology. After all, the pharmaceutical market is constantly emphasizing to hand over professional affairs to professional people. The same is true in stage.

For BIOTECH companies, focusing on research and development and accumulating capital in the early days, and step by step for Biopharma

, Maybe even wise.

- END -